Press Release
12 August 2023

Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the forthcoming US launch of its lead program CT001

- **The Loan Facility Agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S has been increased from DKK 5 million to DKK 10 million and the maturity extended until April 2026.**
- **The new loan facility agreement provides Cessatech increased financial flexibility and support for the upcoming US launch of CT001.**
- **To date Cessatech has not drawn on the facility and the Loan Facility Agreement can potentially be converted into shares on market conditions.**

On 12 August – Cessatech A/S ("Cessatech" or "the Company") announces that the Company has extended the Loan Facility Agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S. The agreement was initiated in August 2023 and has not yet been drawn upon. The agreement has been extended until 2026 and increased from DKK 5 million to DKK 10 million. The loan terms have been agreed upon market terms. Any amounts drawn by the Company (including accrued interest) shall rank equal with the Company's other creditors.

Jes Trygved, CEO Cessatech
"The extended loan facility gives us more financial flexibility during the next 18-24 months for the upcoming launch US launch and operations as we still expect to begin generating revenues in 2024. We are very pleased that the group of investors providing the loan facility supports Cessatech and our work to bring solutions to the unmet medical need of treating children who are experiencing acute pain. In addition, it is important to Cessatech that the Loan Facility Agreement may be converted into shares."

For more information about Cessatech, please contact:
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

About Cessatech
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development, and CT002 is at the early development phase.